Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) – Equities research analysts at Leerink Partnrs dropped their Q2 2025 earnings per share estimates for shares of Sarepta Therapeutics in a research report issued on Wednesday, July 16th. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will post earnings per share of $0.72 for the quarter, down from their prior forecast of $2.25. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.67 per share. Leerink Partnrs also issued estimates for Sarepta Therapeutics’ Q3 2025 earnings at $0.52 EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($2.50) EPS, Q3 2026 earnings at $3.10 EPS, Q4 2026 earnings at $1.56 EPS and FY2026 earnings at $6.63 EPS.
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). The company had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The company’s revenue was up 80.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.73 EPS.
A number of other equities research analysts also recently weighed in on the company. TD Cowen downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $24.00 target price on the stock. in a research report on Wednesday, June 18th. BMO Capital Markets downgraded Sarepta Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $120.00 to $70.00 in a research report on Monday, June 16th. Needham & Company LLC downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. UBS Group decreased their target price on Sarepta Therapeutics from $188.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, May 8th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $40.00 target price (down from $113.00) on shares of Sarepta Therapeutics in a research report on Monday, June 16th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $56.50.
View Our Latest Stock Analysis on Sarepta Therapeutics
Sarepta Therapeutics Stock Performance
NASDAQ SRPT opened at $14.07 on Monday. The company’s fifty day moving average is $28.42 and its two-hundred day moving average is $67.58. Sarepta Therapeutics has a 52-week low of $12.81 and a 52-week high of $150.48. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -5.23 and a beta of 0.45.
Hedge Funds Weigh In On Sarepta Therapeutics
A number of institutional investors have recently modified their holdings of the stock. Byrne Asset Management LLC bought a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $30,000. Center for Financial Planning Inc. bought a new position in Sarepta Therapeutics in the 1st quarter valued at $31,000. Logan Capital Management Inc. bought a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $61,000. Ancora Advisors LLC lifted its stake in shares of Sarepta Therapeutics by 150.0% during the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 300 shares during the period. Finally, Hurley Capital LLC bought a new position in Sarepta Therapeutics in the fourth quarter valued at about $76,000. 86.68% of the stock is owned by institutional investors.
About Sarepta Therapeutics
(Get Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Read More
Receive News & Ratings for Sarepta Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sarepta Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
